27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Allergan PLC (NYSE: AGN) delivered below than expected results for the third quarter.
- Reports adjusted EPS of $3.32, misses by $0.26.
- Generates revenue of $3.62 billion, shy of the estimates of $0.07 billion.
- Completed $5 billion share buyback program ahead of schedule.
- Reveals fresh $10 billion accelerated share buyback program.
- Initiates cash dividend in 2017.
- Updates full year adjusted EPS $13.30-$13.50 versus $13.94 expectations.
- Updates revenue of $14.45-$14.65 billion versus $14.72 billion expectations.
CEO and President Brent Saunders commented, "Allergan continues to be among the best positioned biopharmaceutical companies to deliver long-term growth. Our top global products powered our performance in the third quarter, including BOTOX®, RESTASIS®, LINZESS® / CONSTELLA® and Fillers. Our R&D teams continued to deliver exceptional results and build our pipeline with our Open Science R&D approach, including the six new stepping stone acquisitions we announced this quarter. And we substantially added to our share repurchase plan and added a first-ever dividend payable in 2017 to maximize shareholder value.”
The stock edged up by 0.65 percent to $210.01 in the pre-market session.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!